Complement Therapeutics

CompanyUnited Kingdom

Complement Therapeutics develops one asset, in phase 1 (CTX001 in anemia). Mostly gene therapy; based in the United Kingdom.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1
  • CTX001

    Phase 1, Gene therapy, anemia, chronic kidney disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals2
  • Similar companies6

Intelligence